Skip to main content

Advertisement

Table 1 Baseline characteristics of the population

From: Renin Angiotensin system-modifying therapies are associated with improved pulmonary health

Variable ACE-Is ARBs Control
Number of Subjects (%) 101,613 (47.2) 24,526 (11.4) 89,086 (41.4)
Sex (%)
 Female 47,195 (46.5) 12,550 (51.2) 52,189 (58.6)
Mean age (years ± SD) 62.91 (13.5) 62.05 (±13.3) 64.20 (±13.8)
Race (%)
 White 56,522 (55.6) 11,502 (46.9) 50,660 (56.9)
 Black 5032 (5.0) 1531 (6.2) 7359 (8.3)
 Others 2854 (2.8) 834 (3.4) 2432 (2.7)
 Unknown 37,195 (36.6) 10,659 (43.5) 28,635 (32.1)
Comorbidities (ICD-9 codes)
 Infectious (001–139) 14,183 (14.0) 3299 (13.5) 15,016 (16.9)
 Blood (280–289) 15,762 (15.5) 3858 (15.7) 18,105 (20.3)
 AMI (410) 3081 (3.0) 308 (1.3) 1503 (1.7)
 Angina pectoris (413) 4022 (4.0) 775 (3.2) 3594 (4.0)
 Cardiac dysrhythmias (427) 13,591 (13.4) 2805 (11.4) 15,769 (17.7)
 Heart failure (428) 4702 (4.6) 869 (3.5) 6859 (7.7)
 Respiratory (460–519) 33,081 (32.6) 7995 (32.6) 28,836 (32.4)
Other Treatments
 Statin (%) 43,298 (42.6) 9393 (38.3) 33,043 (37.1)
 Flu vaccine (%) 35,550 (35.0) 7914 (32.3) 32,498 (36.5)
 T2D (%) 5423 (5.3) 1218 (5.0) 5281 (5.9)
Other Information
 Mean follow up time (days) 1663.08 1603.33 1664.05
 STD (+/−) 593.43 611.68 599.37
  1. Medicare (a small % of the Humana dataset) does not report patient race and will be reported as unknown here. Incidence of comorbidities in the 12 month pre-index period for all study groups. *Respiratory does not include codes covered by infectious, inflammatory or structural outcomes